Abstract
To obtain information on anti-prostate cancer (CaP) activities of piceatannol, a metabolite biotransformed from resveratrol by cytochrome P450 CYP1B, CWR22Rv1 cells were incubated with increasing dose of piceatannol. Proliferation and apoptosis assays in exposed cells showed that piceatannol produced inhibition comparable to resveratrol. To determine whether quinone reductase 2 (NQO2) plays a role in the observed effects, in silico analysis was performed. Piceatannol interacted with NQO2 at the same site as resveratrol forming hydrogen bond with asparagine-161 (ASN161). NQO2 mediated anti-CaP effects of piceatannol were also tested and supported by the attenuation of anti-proliferative activity and reduction in extent of inhibition of NQO2 activity by piceatannol in NQO2-knockdown cells relative to NQO2- expressing cells, and by the copious expression of CYP1B in CWR22Rv1 cells. These results show that NQO2 is an intracellular target for piceatannol, suggesting that CaP prevention by resveratrol may be partially attributed to its conversion to piceatannol.
Keywords: Resveratrol, piceatannol, biotransformation, chemoprevention, cytochrome P450 CYP1B1, CWR22Rv1 prostate cancer cells, in silico analysis, NQO2, NQO2 knockdown.
Current Medicinal Chemistry
Title:In Silico and Biochemical Analyses Identify Quinone Reductase 2 as a Target of Piceatannol
Volume: 20 Issue: 33
Author(s): Tze-Chen Hsieh, Dylan John Bennett, Yong-Syu Lee, Erxi Wu and Joseph M. Wu
Affiliation:
Keywords: Resveratrol, piceatannol, biotransformation, chemoprevention, cytochrome P450 CYP1B1, CWR22Rv1 prostate cancer cells, in silico analysis, NQO2, NQO2 knockdown.
Abstract: To obtain information on anti-prostate cancer (CaP) activities of piceatannol, a metabolite biotransformed from resveratrol by cytochrome P450 CYP1B, CWR22Rv1 cells were incubated with increasing dose of piceatannol. Proliferation and apoptosis assays in exposed cells showed that piceatannol produced inhibition comparable to resveratrol. To determine whether quinone reductase 2 (NQO2) plays a role in the observed effects, in silico analysis was performed. Piceatannol interacted with NQO2 at the same site as resveratrol forming hydrogen bond with asparagine-161 (ASN161). NQO2 mediated anti-CaP effects of piceatannol were also tested and supported by the attenuation of anti-proliferative activity and reduction in extent of inhibition of NQO2 activity by piceatannol in NQO2-knockdown cells relative to NQO2- expressing cells, and by the copious expression of CYP1B in CWR22Rv1 cells. These results show that NQO2 is an intracellular target for piceatannol, suggesting that CaP prevention by resveratrol may be partially attributed to its conversion to piceatannol.
Export Options
About this article
Cite this article as:
Hsieh Tze-Chen, Bennett John Dylan, Lee Yong-Syu, Wu Erxi and Wu M. Joseph, In Silico and Biochemical Analyses Identify Quinone Reductase 2 as a Target of Piceatannol, Current Medicinal Chemistry 2013; 20 (33) . https://dx.doi.org/10.2174/09298673113209990252
DOI https://dx.doi.org/10.2174/09298673113209990252 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets The Anti-Inflammatory Role of Annexin-1 in Arthritis
Current Rheumatology Reviews Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Biological Interfacial Engineering for Metastatic Cancer Diagnosis and Intervention
Current Medicinal Chemistry Reconstruction, Topological and Gene Ontology Enrichment Analysis of Cancerous Gene Regulatory Network Modules
Current Bioinformatics Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Influence of Biological and Technical Covariates on Non-targeted Metabolite Profiling in a Large-scale Epidemiological Study
Current Metabolomics Meet Our Editorial Board Member:
Current Cancer Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Patenting the Gene-Hubs of Endoplasmic Reticulum Stress: The Systems Biology Approach
Recent Patents on Biotechnology Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Novel N-mustard-benzimidazoles/benzothiazoles Hybrids, Synthesis and Anticancer Evaluation
Anti-Cancer Agents in Medicinal Chemistry